Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 7/2015

01.06.2015 | Original Article

Brain 18F-DOPA PET and cognition in de novo Parkinson’s disease

verfasst von: Agnese Picco, Silvia Morbelli, Arnoldo Piccardo, Dario Arnaldi, Nicola Girtler, Andrea Brugnolo, Irene Bossert, Lucio Marinelli, Antonio Castaldi, Fabrizio De Carli, Claudio Campus, Giovanni Abbruzzese, Flavio Nobili

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The role of mesocortical dopaminergic pathways in the cognitive function of patients with early Parkinson’s disease (PD) needs to be further clarified.

Methods

The study groups comprised 15 drug-naive patients with de novo PD and 10 patients with essential tremor (controls) who underwent 18F-DOPA PET (static acquisition, normalization on mean cerebellar counts) and an extended neuropsychological test battery. Factor analysis with varimax rotation was applied to the neuropsychological test scores, to yield five factors from 16 original scores, which explained 82 % of the total variance. Correlations between cognitive factors and 18F-DOPA uptake were assessed with SPM8, taking age and gender as nuisance variables.

Results

18F-DOPA uptake was significantly lower in PD patients than in controls in the bilateral striatum, mainly in the more affected (right) hemisphere, and in a small right temporal region. Significant positive correlations were found only in PD patients between the executive factor and 18F-DOPA uptake in the bilateral anterior cingulate cortex (ACC) and the middle frontal gyrus, between the verbal fluency factor and 18F-DOPA uptake in left BA 46 and the bilateral striatum, and between the visuospatial factor and 18F-DOPA uptake in the left ACC and bilateral striatum. No correlations were found between 18F-DOPA uptake and either the verbal memory factor or the abstraction–working memory factor.

Conclusion

These data clarify the role of the mesocortical dopaminergic pathways in cognitive function in early PD, highlighting the medial frontal lobe, anterior cingulate, and left BA 46 as the main sites of cortical correlation with executive and language functions.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol. 2010;9:1200–13.CrossRefPubMed Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol. 2010;9:1200–13.CrossRefPubMed
2.
Zurück zum Zitat Claassen DO, Wylie SA. Trends and issues in characterizing early cognitive changes in Parkinson’s disease. Curr Neurol Neurosci Rep. 2012;12:695–702.CrossRefPubMedCentralPubMed Claassen DO, Wylie SA. Trends and issues in characterizing early cognitive changes in Parkinson’s disease. Curr Neurol Neurosci Rep. 2012;12:695–702.CrossRefPubMedCentralPubMed
3.
Zurück zum Zitat Arnaldi D, Campus C, Ferrara M, et al. What predicts cognitive decline in de novo Parkinson’s disease? Neurobiol Aging. 2012;33:1127.e11–20.CrossRef Arnaldi D, Campus C, Ferrara M, et al. What predicts cognitive decline in de novo Parkinson’s disease? Neurobiol Aging. 2012;33:1127.e11–20.CrossRef
4.
Zurück zum Zitat Olde Dubbelink KT, Hillebrand A, Twisk JW, et al. Predicting dementia in Parkinson disease by combining neurophysiologic and cognitive markers. Neurology. 2014;82:263–70.CrossRefPubMed Olde Dubbelink KT, Hillebrand A, Twisk JW, et al. Predicting dementia in Parkinson disease by combining neurophysiologic and cognitive markers. Neurology. 2014;82:263–70.CrossRefPubMed
5.
Zurück zum Zitat Barone P. Neurotransmission in Parkinson’s disease: beyond dopamine. Eur J Neurol. 2010;17:364–76.CrossRefPubMed Barone P. Neurotransmission in Parkinson’s disease: beyond dopamine. Eur J Neurol. 2010;17:364–76.CrossRefPubMed
6.
Zurück zum Zitat Brooks DJ, Pavese N. Imaging biomarkers in Parkinson’s disease. Prog Neurobiol. 2011;95:614–28.CrossRefPubMed Brooks DJ, Pavese N. Imaging biomarkers in Parkinson’s disease. Prog Neurobiol. 2011;95:614–28.CrossRefPubMed
7.
Zurück zum Zitat Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegener Dis. 2013;11:79–92.CrossRefPubMed Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegener Dis. 2013;11:79–92.CrossRefPubMed
8.
Zurück zum Zitat Marié RM, Barré L, Dupuy B, et al. Relationships between striatal dopamine denervation and frontal executive tests in Parkinson’s disease. Neurosci Lett. 1999;260:77–80.CrossRefPubMed Marié RM, Barré L, Dupuy B, et al. Relationships between striatal dopamine denervation and frontal executive tests in Parkinson’s disease. Neurosci Lett. 1999;260:77–80.CrossRefPubMed
9.
Zurück zum Zitat Rinne JO, Portin R, Ruottinen H, et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol. 2000;57:470–5.CrossRefPubMed Rinne JO, Portin R, Ruottinen H, et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol. 2000;57:470–5.CrossRefPubMed
10.
Zurück zum Zitat Brück A, Portin R, Lindell A, et al. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson’s disease is related to dopaminergic hypofunction in the caudate nucleus. Neurosci Lett. 2001;311:81–4.CrossRefPubMed Brück A, Portin R, Lindell A, et al. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson’s disease is related to dopaminergic hypofunction in the caudate nucleus. Neurosci Lett. 2001;311:81–4.CrossRefPubMed
11.
Zurück zum Zitat Cropley VL, Fujita M, Innis RB, et al. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry. 2006;59:898–907.CrossRefPubMed Cropley VL, Fujita M, Innis RB, et al. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry. 2006;59:898–907.CrossRefPubMed
12.
Zurück zum Zitat van Beilen M, Leenders KL. Putamen FDOPA uptake and its relationship to cognitive functioning in PD. J Neurol Sci. 2006;248:68–71.CrossRefPubMed van Beilen M, Leenders KL. Putamen FDOPA uptake and its relationship to cognitive functioning in PD. J Neurol Sci. 2006;248:68–71.CrossRefPubMed
13.
Zurück zum Zitat Jokinen P, Brück A, Aalto S, et al. Impaired cognitive performance in Parkinson’s disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord. 2009;15:88–93.CrossRefPubMed Jokinen P, Brück A, Aalto S, et al. Impaired cognitive performance in Parkinson’s disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord. 2009;15:88–93.CrossRefPubMed
14.
Zurück zum Zitat Nobili F, Campus C, Arnaldi D, et al. Cognitive-nigrostriatal relationships in de novo, drug-naïve Parkinson’s disease patients: a [I-123]FP-CIT SPECT study. Mov Disord. 2010;25:35–43.CrossRefPubMed Nobili F, Campus C, Arnaldi D, et al. Cognitive-nigrostriatal relationships in de novo, drug-naïve Parkinson’s disease patients: a [I-123]FP-CIT SPECT study. Mov Disord. 2010;25:35–43.CrossRefPubMed
15.
Zurück zum Zitat Jokinen P, Karrasch M, Brück A, et al. Cognitive slowing in Parkinson’s disease is related to frontostriatal dopaminergic dysfunction. J Neurol Sci. 2013;329:23–8.CrossRefPubMed Jokinen P, Karrasch M, Brück A, et al. Cognitive slowing in Parkinson’s disease is related to frontostriatal dopaminergic dysfunction. J Neurol Sci. 2013;329:23–8.CrossRefPubMed
16.
Zurück zum Zitat Holthoff VA, Vieregge P, Kessler J, et al. Discordant twins with Parkinson’s disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol. 1994;36:176–82.CrossRefPubMed Holthoff VA, Vieregge P, Kessler J, et al. Discordant twins with Parkinson’s disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol. 1994;36:176–82.CrossRefPubMed
17.
Zurück zum Zitat Calvini P, Rodriguez G, Inguglia F, et al. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging. 2007;34:1240–53.CrossRefPubMed Calvini P, Rodriguez G, Inguglia F, et al. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging. 2007;34:1240–53.CrossRefPubMed
18.
Zurück zum Zitat Eshuis SA, Jager PL, Maguire RP, et al. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson’s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2009;36:454–62.CrossRefPubMed Eshuis SA, Jager PL, Maguire RP, et al. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson’s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2009;36:454–62.CrossRefPubMed
19.
Zurück zum Zitat Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ. Progression of monoaminergic dysfunction in Parkinson’s disease: a longitudinal 18F-dopa PET study. Neuroimage. 2011;56:1463–8.CrossRefPubMed Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ. Progression of monoaminergic dysfunction in Parkinson’s disease: a longitudinal 18F-dopa PET study. Neuroimage. 2011;56:1463–8.CrossRefPubMed
20.
Zurück zum Zitat Hirano S, Shinotoh H, Eidelberg D. Functional brain imaging of cognitive dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2012;83:963–9.CrossRefPubMed Hirano S, Shinotoh H, Eidelberg D. Functional brain imaging of cognitive dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2012;83:963–9.CrossRefPubMed
21.
Zurück zum Zitat Moore RY, Whone AL, Brooks DJ. Extrastriatal monoamine neuron function in Parkinson’s disease: an 18F-dopa PET study. Neurobiol Dis. 2008;29:381–90.CrossRefPubMed Moore RY, Whone AL, Brooks DJ. Extrastriatal monoamine neuron function in Parkinson’s disease: an 18F-dopa PET study. Neurobiol Dis. 2008;29:381–90.CrossRefPubMed
22.
Zurück zum Zitat Nagano-Saito A, Kato T, Arahata Y, et al. Cognitive- and motor-related regions in Parkinson’s disease: FDOPA and FDG PET studies. Neuroimage. 2004;22:553–61.CrossRefPubMed Nagano-Saito A, Kato T, Arahata Y, et al. Cognitive- and motor-related regions in Parkinson’s disease: FDOPA and FDG PET studies. Neuroimage. 2004;22:553–61.CrossRefPubMed
23.
Zurück zum Zitat Brück A, Aalto S, Nurmi E, et al. Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson’s disease. Neurobiol Aging. 2005;26:891–8.CrossRefPubMed Brück A, Aalto S, Nurmi E, et al. Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson’s disease. Neurobiol Aging. 2005;26:891–8.CrossRefPubMed
24.
Zurück zum Zitat Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33–9.CrossRefPubMed Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33–9.CrossRefPubMed
25.
Zurück zum Zitat Annett M. A classification of hand preference by association analysis. Br J Psychol. 1970;61:303–21.CrossRefPubMed Annett M. A classification of hand preference by association analysis. Br J Psychol. 1970;61:303–21.CrossRefPubMed
26.
Zurück zum Zitat Katz S, Downs TD, Cash HR, et al. Progress in development of the index of ADL. Gerontologist. 1970;10:20–30.CrossRefPubMed Katz S, Downs TD, Cash HR, et al. Progress in development of the index of ADL. Gerontologist. 1970;10:20–30.CrossRefPubMed
27.
Zurück zum Zitat Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–86.CrossRefPubMed Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–86.CrossRefPubMed
28.
Zurück zum Zitat Deuschl G, Bain P, Brin M. Consensus statement of the movement disorder society on tremor. Ad hoc scientific committee. Mov Disord. 1998;13 Suppl 3:2–23.PubMed Deuschl G, Bain P, Brin M. Consensus statement of the movement disorder society on tremor. Ad hoc scientific committee. Mov Disord. 1998;13 Suppl 3:2–23.PubMed
29.
Zurück zum Zitat Brooks DJ, Playford ED, Ibanez V, et al. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology. 1992;42:1554–60.CrossRefPubMed Brooks DJ, Playford ED, Ibanez V, et al. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology. 1992;42:1554–60.CrossRefPubMed
30.
Zurück zum Zitat Walterfang M, van de Warrenburg BP. Cognitive impairment in "Other" movement disorders: hidden defects and valuable clues. Mov Disord. 2014;29:694–703.CrossRefPubMed Walterfang M, van de Warrenburg BP. Cognitive impairment in "Other" movement disorders: hidden defects and valuable clues. Mov Disord. 2014;29:694–703.CrossRefPubMed
31.
Zurück zum Zitat Kumakura Y, Cumming P. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neuroscientist. 2009;15:635–50.CrossRefPubMed Kumakura Y, Cumming P. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neuroscientist. 2009;15:635–50.CrossRefPubMed
32.
Zurück zum Zitat Ishikawa T, Dhawan V, Chaly T, et al. Clinical significance of striatal DOPA decarboxylase activity in Parkinson’s disease. J Nucl Med. 1996;37:216–22.PubMed Ishikawa T, Dhawan V, Chaly T, et al. Clinical significance of striatal DOPA decarboxylase activity in Parkinson’s disease. J Nucl Med. 1996;37:216–22.PubMed
33.
Zurück zum Zitat Dhawan V, Ma Y, Pillai V, et al. Comparative analysis of striatal FDOPA uptake in Parkinson’s disease: ratio method versus graphical approach. J Nucl Med. 2002;43:1324–30.PubMed Dhawan V, Ma Y, Pillai V, et al. Comparative analysis of striatal FDOPA uptake in Parkinson’s disease: ratio method versus graphical approach. J Nucl Med. 2002;43:1324–30.PubMed
34.
Zurück zum Zitat Jokinen P, Helenius H, Rauhala E, et al. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med. 2009;50:893–9.CrossRefPubMed Jokinen P, Helenius H, Rauhala E, et al. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med. 2009;50:893–9.CrossRefPubMed
35.
Zurück zum Zitat Jaimini A, Tripathi M, D’Souza MM, et al. Utility of intrastriatal ratios of FDOPA to differentiate idiopathic Parkinson’s disease from atypical parkinsonian disorders. Nucl Med Commun. 2013;34:426–31.CrossRefPubMed Jaimini A, Tripathi M, D’Souza MM, et al. Utility of intrastriatal ratios of FDOPA to differentiate idiopathic Parkinson’s disease from atypical parkinsonian disorders. Nucl Med Commun. 2013;34:426–31.CrossRefPubMed
36.
Zurück zum Zitat Eshuis SA, Maguire RP, Leenders KL, et al. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2006;33:200–9.CrossRefPubMed Eshuis SA, Maguire RP, Leenders KL, et al. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2006;33:200–9.CrossRefPubMed
37.
Zurück zum Zitat Gispert JD, Pascau J, Reig S, et al. Influence of the normalization template on the outcome of statistical parametric mapping of PET scans. Neuroimage. 2003;19:601–12.CrossRefPubMed Gispert JD, Pascau J, Reig S, et al. Influence of the normalization template on the outcome of statistical parametric mapping of PET scans. Neuroimage. 2003;19:601–12.CrossRefPubMed
38.
Zurück zum Zitat Scherfler C, Khan NL, Pavese N, et al. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain. 2004;127:1332–42.CrossRefPubMed Scherfler C, Khan NL, Pavese N, et al. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain. 2004;127:1332–42.CrossRefPubMed
39.
Zurück zum Zitat Cheesman AL, Barker RA, Lewis SJ, et al. Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2005;76:1204–10.CrossRefPubMedCentralPubMed Cheesman AL, Barker RA, Lewis SJ, et al. Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2005;76:1204–10.CrossRefPubMedCentralPubMed
40.
Zurück zum Zitat Oishi N, Udaka F, Kameyama M, et al. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology. 2005;65:1708–15.CrossRefPubMed Oishi N, Udaka F, Kameyama M, et al. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology. 2005;65:1708–15.CrossRefPubMed
41.
Zurück zum Zitat Eickhoff SB, Laird AR, Grefkes C, et al. Coordinate-based activation likelihood estimation meta-analysis of neuroimaging data: a random-effects approach based on empirical estimates of spatial uncertainty. Hum Brain Mapp. 2009;30:2907–26.CrossRefPubMedCentralPubMed Eickhoff SB, Laird AR, Grefkes C, et al. Coordinate-based activation likelihood estimation meta-analysis of neuroimaging data: a random-effects approach based on empirical estimates of spatial uncertainty. Hum Brain Mapp. 2009;30:2907–26.CrossRefPubMedCentralPubMed
42.
Zurück zum Zitat Floresco SB. Prefrontal dopamine and behavioral flexibility: shifting from an "inverted-U" toward a family of functions. Front Neurosci. 2013;7:62.CrossRefPubMedCentralPubMed Floresco SB. Prefrontal dopamine and behavioral flexibility: shifting from an "inverted-U" toward a family of functions. Front Neurosci. 2013;7:62.CrossRefPubMedCentralPubMed
43.
Zurück zum Zitat Fleury V, Cousin E, Czernecki V, et al. Dopaminergic modulation of emotional conflict in Parkinson’s disease. Front Aging Neurosci. 2014;6:164.CrossRefPubMedCentralPubMed Fleury V, Cousin E, Czernecki V, et al. Dopaminergic modulation of emotional conflict in Parkinson’s disease. Front Aging Neurosci. 2014;6:164.CrossRefPubMedCentralPubMed
44.
Zurück zum Zitat Berger B, Gaspar P, Verney C. Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. Trends Neurosci. 1991;14:21–7.CrossRefPubMed Berger B, Gaspar P, Verney C. Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. Trends Neurosci. 1991;14:21–7.CrossRefPubMed
45.
Zurück zum Zitat Tinaz S, Schendan HE, Stern CE. Fronto-striatal deficit in Parkinson’s disease during semantic event sequencing. Neurobiol Aging. 2008;29:397–407.CrossRefPubMedCentralPubMed Tinaz S, Schendan HE, Stern CE. Fronto-striatal deficit in Parkinson’s disease during semantic event sequencing. Neurobiol Aging. 2008;29:397–407.CrossRefPubMedCentralPubMed
46.
Zurück zum Zitat Ellfolk U, Joutsa J, Rinne JO, et al. Striatal volume is related to phonemic verbal fluency but not to semantic or alternating verbal fluency in early Parkinson’s disease. J Neural Transm. 2014;121:33–40.CrossRefPubMedCentralPubMed Ellfolk U, Joutsa J, Rinne JO, et al. Striatal volume is related to phonemic verbal fluency but not to semantic or alternating verbal fluency in early Parkinson’s disease. J Neural Transm. 2014;121:33–40.CrossRefPubMedCentralPubMed
47.
Zurück zum Zitat Ullman MT. Is Broca’s area part of a basal ganglia thalamocortical circuit? Cortex. 2006;42:480–5.CrossRefPubMed Ullman MT. Is Broca’s area part of a basal ganglia thalamocortical circuit? Cortex. 2006;42:480–5.CrossRefPubMed
48.
Zurück zum Zitat Nobili F, Arnaldi D, Campus C, et al. Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2011;38:2209–18.CrossRefPubMed Nobili F, Arnaldi D, Campus C, et al. Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2011;38:2209–18.CrossRefPubMed
49.
Zurück zum Zitat Tomasi D, Volkow ND, Wang R, et al. Dopamine transporters in striatum correlate with deactivation in the default mode network during visuospatial attention. PLoS One. 2009;4:e6102.CrossRefPubMedCentralPubMed Tomasi D, Volkow ND, Wang R, et al. Dopamine transporters in striatum correlate with deactivation in the default mode network during visuospatial attention. PLoS One. 2009;4:e6102.CrossRefPubMedCentralPubMed
50.
Zurück zum Zitat Manganelli F, Vitale C, Santangelo G, et al. Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson’s disease. Brain. 2009;132:2350–5.CrossRefPubMedCentralPubMed Manganelli F, Vitale C, Santangelo G, et al. Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson’s disease. Brain. 2009;132:2350–5.CrossRefPubMedCentralPubMed
51.
Zurück zum Zitat Broussolle E, Dentresangle C, Landais P, et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson’s disease. J Neurol Sci. 1999;166:141–51.CrossRefPubMed Broussolle E, Dentresangle C, Landais P, et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson’s disease. J Neurol Sci. 1999;166:141–51.CrossRefPubMed
52.
Zurück zum Zitat Polito C, Berti V, Ramat S, et al. Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson’s disease. Neurobiol Aging. 2012;33:206.e29–39.CrossRef Polito C, Berti V, Ramat S, et al. Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson’s disease. Neurobiol Aging. 2012;33:206.e29–39.CrossRef
53.
Zurück zum Zitat Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology. 2010;74:885–92.CrossRefPubMed Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology. 2010;74:885–92.CrossRefPubMed
54.
Zurück zum Zitat Rakshi JS, Uema T, Ito K, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson’s disease. A 3D [(18)F]dopa-PET study. Brain. 1999;122:1637–50.CrossRefPubMed Rakshi JS, Uema T, Ito K, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson’s disease. A 3D [(18)F]dopa-PET study. Brain. 1999;122:1637–50.CrossRefPubMed
55.
Zurück zum Zitat Kaasinen V, Nurmi E, Brück A, et al. Increased frontal [(18)F]fluorodopa uptake in early Parkinson’s disease: sex differences in the prefrontal cortex. Brain. 2001;124:1125–30.CrossRefPubMed Kaasinen V, Nurmi E, Brück A, et al. Increased frontal [(18)F]fluorodopa uptake in early Parkinson’s disease: sex differences in the prefrontal cortex. Brain. 2001;124:1125–30.CrossRefPubMed
56.
Zurück zum Zitat Brück A, Aalto S, Nurmi E, et al. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson’s disease: a two-year follow-up study. Mov Disord. 2006;21:958–63.CrossRefPubMed Brück A, Aalto S, Nurmi E, et al. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson’s disease: a two-year follow-up study. Mov Disord. 2006;21:958–63.CrossRefPubMed
Metadaten
Titel
Brain 18F-DOPA PET and cognition in de novo Parkinson’s disease
verfasst von
Agnese Picco
Silvia Morbelli
Arnoldo Piccardo
Dario Arnaldi
Nicola Girtler
Andrea Brugnolo
Irene Bossert
Lucio Marinelli
Antonio Castaldi
Fabrizio De Carli
Claudio Campus
Giovanni Abbruzzese
Flavio Nobili
Publikationsdatum
01.06.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2015
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3039-0

Weitere Artikel der Ausgabe 7/2015

European Journal of Nuclear Medicine and Molecular Imaging 7/2015 Zur Ausgabe